About
Plakous Therapeutics develops a human placental extract (HPE) biologic intended to treat inflammation-driven diseases, with preclinical programs focused on conditions such as necrotizing enterocolitis (NEC) and pediatric malabsorption. The company has received pediatric and orphan drug designations and is supported by a Phase IIB SBIR grant from the U.S. National Institutes of Health.
Explore Plakous Therapeutics's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.